Azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
US-12180196-B2 · Dec 31, 2024 · US
Pharmaceutical formulations comprising an insulin derivative
US9034818B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9034818-B2 |
| Application number | US-66415608-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 12, 2008 |
| Priority date | Jun 13, 2007 |
| Publication date | May 19, 2015 |
| Grant date | May 19, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention concerns a soluble pharmaceutical formulation comprising an insulin derivative wherein the formulation further comprises more than 4 zinc atoms per 6 molecules of the insulin derivative, and a citric acid monohydrate and/or a histidine compound used in an amount sufficient to increase the tendency of the insulin derivative to self-associate into dodecamers. The invention further comprises a process for preparing the soluble pharmaceutical formulation.
First claim
Opening claim text (preview).
The invention claimed is: 1. A soluble pharmaceutical formulation comprising dodecamers of insulin derivative wherein the formulation further comprises a) more than 4 zinc atoms per 6 molecules of the insulin derivative, b) citric acid monohydrate and/or a histidine compound used in an amount sufficient to increase the tendency of the insulin derivative to self-associate into dodecamers, wherein the insulin derivative is a parent insulin with an ε-amino group of a Lys residue…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
- A61K9/0019Primary
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9034818B2 cover?
- The invention concerns a soluble pharmaceutical formulation comprising an insulin derivative wherein the formulation further comprises more than 4 zinc atoms per 6 molecules of the insulin derivative, and a citric acid monohydrate and/or a histidine compound used in an amount sufficient to increase the tendency of the insulin derivative to self-associate into dodecamers. The invention further c…
- Who is the assignee on this patent?
- Poulsen Christian, Huus Kasper, Hubalek Frantisek, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K9/0019. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 19 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).